Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Scholar Rock Holding

DB:2QK
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2QK
DB
$452M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The last earnings update was 28 days ago. More info.


Add to Portfolio Compare Print
  • Scholar Rock Holding has significant price volatility in the past 3 months.
2QK Share Price and Events
7 Day Returns
48.7%
DB:2QK
2.2%
DE Biotechs
7.2%
DE Market
1 Year Returns
-
DB:2QK
-9%
DE Biotechs
-14.3%
DE Market
2QK Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Scholar Rock Holding (2QK) 48.7% 12.1% 20.9% - - -
DE Biotechs 2.2% 0.4% -23.6% -9% 16.2% -12.2%
DE Market 7.2% -3.5% -22% -14.3% -19.9% -25.7%
1 Year Return vs Industry and Market
  • No trading data on 2QK.
  • No trading data on 2QK.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

2QK Value

 Is Scholar Rock Holding undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Scholar Rock Holding. This is due to cash flow or dividend data being unavailable. The share price is €13.9.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Scholar Rock Holding's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Scholar Rock Holding's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2QK PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.85
NasdaqGS:SRRK Share Price ** NasdaqGS (2020-04-08) in USD $15.15
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 42.02x
Germany Market PE Ratio Median Figure of 403 Publicly-Listed Companies 17.05x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Scholar Rock Holding.

DB:2QK PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:SRRK Share Price ÷ EPS (both in USD)

= 15.15 ÷ -1.85

-8.18x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Scholar Rock Holding is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Scholar Rock Holding is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Scholar Rock Holding's expected growth come at a high price?
Raw Data
DB:2QK PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -8.18x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
28.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Scholar Rock Holding, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Scholar Rock Holding's assets?
Raw Data
DB:2QK PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $3.79
NasdaqGS:SRRK Share Price * NasdaqGS (2020-04-08) in USD $15.15
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.4x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.5x
DB:2QK PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:SRRK Share Price ÷ Book Value per Share (both in USD)

= 15.15 ÷ 3.79

4x

* Primary Listing of Scholar Rock Holding.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Scholar Rock Holding is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Scholar Rock Holding's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Scholar Rock Holding has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

2QK Future Performance

 How is Scholar Rock Holding expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
28.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Scholar Rock Holding expected to grow at an attractive rate?
  • Scholar Rock Holding's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Scholar Rock Holding's earnings growth is expected to exceed the Germany market average.
  • Scholar Rock Holding's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:2QK Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:2QK Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 28.9%
DB:2QK Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 46.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 37.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.3%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.2%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2QK Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2QK Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 317 106 2
2023-12-31 95 -47 2
2022-12-31 34 -108 3
2021-12-31 22 -92 -91 4
2020-12-31 41 -48 -47 4
2020-04-09
DB:2QK Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 20 -63 -51
2019-09-30 13 8 -54
2019-06-30 8 14 -49
2019-03-31 3 19 -51
2018-12-31 25 -49
2018-09-30 -37 -43
2018-06-30 -33 -38
2018-03-31 -27 -29
2017-12-31 -22 -25

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Scholar Rock Holding's earnings are expected to grow significantly at over 20% yearly.
  • Scholar Rock Holding's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2QK Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Scholar Rock Holding Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2QK Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 2.40 6.22 -0.56 4.00
2023-12-31 -1.29 1.36 -2.90 4.00
2022-12-31 -2.88 -1.74 -4.35 4.00
2021-12-31 -2.65 -2.02 -3.25 5.00
2020-12-31 -1.61 -1.32 -1.84 4.00
2020-04-09
DB:2QK Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.85
2019-09-30 -2.06
2019-06-30 -1.95
2019-03-31 -2.40
2018-12-31 -3.15
2018-09-30 -4.32
2018-06-30 -9.06
2018-03-31 -15.09
2017-12-31 -15.30

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Scholar Rock Holding will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Scholar Rock Holding's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Scholar Rock Holding has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

2QK Past Performance

  How has Scholar Rock Holding performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Scholar Rock Holding's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Scholar Rock Holding does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Scholar Rock Holding's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Scholar Rock Holding's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Scholar Rock Holding's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Scholar Rock Holding Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2QK Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 20.49 -51.00 20.82
2019-09-30 12.92 -54.39 20.40
2019-06-30 8.15 -49.01 17.39
2019-03-31 3.11 -51.19 16.14
2018-12-31 -49.33 14.38
2018-09-30 -42.82 10.52
2018-06-30 -37.99 8.51
2018-03-31 -29.16 6.23
2017-12-31 -25.00 5.09
2016-12-31 0.38 -16.21 4.11

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Scholar Rock Holding has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Scholar Rock Holding has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Scholar Rock Holding improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Scholar Rock Holding's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Scholar Rock Holding has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

2QK Health

 How is Scholar Rock Holding's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Scholar Rock Holding's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Scholar Rock Holding is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Scholar Rock Holding's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Scholar Rock Holding's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Scholar Rock Holding has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Scholar Rock Holding Company Filings, last reported 3 months ago.

DB:2QK Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 112.90 0.00 157.45
2019-09-30 121.79 0.00 176.08
2019-06-30 128.96 0.00 185.13
2019-03-31 97.52 0.27 159.67
2018-12-31 106.62 0.42 175.65
2018-09-30 102.34 0.58 103.99
2018-06-30 111.61 0.73 115.06
2018-03-31 47.30 0.89 47.76
2017-12-31 55.71 1.04 57.96
2016-12-31 28.03 1.67 28.04
  • Scholar Rock Holding has no debt.
  • Scholar Rock Holding currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Scholar Rock Holding has sufficient cash runway for 2.4 years based on current free cash flow.
  • Scholar Rock Holding has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of -10.3% each year.
X
Financial health checks
We assess Scholar Rock Holding's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Scholar Rock Holding has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

2QK Dividends

 What is Scholar Rock Holding's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Scholar Rock Holding dividends.
If you bought €2,000 of Scholar Rock Holding shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Scholar Rock Holding's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Scholar Rock Holding's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2QK Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:2QK Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-09

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Scholar Rock Holding has not reported any payouts.
  • Unable to verify if Scholar Rock Holding's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Scholar Rock Holding's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Scholar Rock Holding has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Scholar Rock Holding's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Scholar Rock Holding afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Scholar Rock Holding has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

2QK Management

 What is the CEO of Scholar Rock Holding's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Nagesh Mahanthappa
COMPENSATION $3,042,227
AGE 54
TENURE AS CEO 7.5 years
CEO Bio

Dr. Nagesh K. Mahanthappa, PhD, MBA, serves as the President and Chief Executive Officer for Scholar Rock, Inc. Dr. Mahanthappa has been the President and Chief Executive Officer at Scholar Rock Holding Corp. since October 2012 and also has been its Executive Director since October 2012. He was Vice President of Corporate Development & Operations at Celgene Avilomics Research, Inc. until 2012. He served as Vice President of Corporate Development & Operations at Avila Therapeutics, Inc. He was also a founder of TwistDx, Inc. (now Alere, Inc.) in 2010. He was a founding employee and subsequently Vice President of Scientific and Strategic Development at Alnylam Pharmaceuticals. Serving as a management team member, he initially served as interim head of research during the Alnylam's first year and led business development efforts that resulted in partnerships with Merck, Medtronic, and Novartis. Prior to joining Alnylam, Dr. Mahanthappa served as Manager of Business Development at Vertex Pharmaceuticals and held a series of positions with increasing scientific and commercial responsibility at Ontogeny (now Curis). He serves as a Director of Scholar Rock, LLC. He earned his PhD in neurobiology from the California Institute of Technology, followed by a post-doctoral fellowship at the Massachusetts General Hospital and Harvard Medical School. He received his M.B.A. from the F.W. Olin Graduate School of Management at Babson College and his B.A. in Biology and Chemistry from the University of Colorado, Boulder.

CEO Compensation
  • Nagesh's compensation has increased whilst company is loss making.
  • Nagesh's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Scholar Rock Holding management team in years:

2.1
Average Tenure
54
Average Age
  • The tenure for the Scholar Rock Holding management team is about average.
Management Team

Nagesh Mahanthappa

TITLE
President
COMPENSATION
$3M
AGE
54
TENURE
7.5 yrs

Erin Moore

TITLE
Senior VP of Finance & Interim Principal Accounting Officer
TENURE
1.5 yrs

Alan Buckler

TITLE
Chief Scientific Officer
AGE
59
TENURE
3.4 yrs

Catherine Hu

TITLE
Vice President of Investor Relations & Corporate Communications
TENURE
2.1 yrs

Junlin Ho

TITLE
VP & Head of Corporate Legal

Dodzie Sogah

TITLE
Vice President of Corporate Development & Strategy
TENURE
2.1 yrs

Lisa Price

TITLE
Senior Vice President of Human Resources
TENURE
1 yrs

Yung Chyung

TITLE
Chief Medical Officer
COMPENSATION
$644K
AGE
43
TENURE
4.2 yrs

Greg Carven

TITLE
Senior Vice President of Antibody Discovery & Protein Sciences

George Nomikos

TITLE
VP & Head of Medical Research
TENURE
0.6 yrs
Board of Directors Tenure

Average tenure and age of the Scholar Rock Holding board of directors in years:

5.7
Average Tenure
53
Average Age
  • The tenure for the Scholar Rock Holding board of directors is about average.
Board of Directors

David Hallal

TITLE
Chairman of the Board
COMPENSATION
$922K
AGE
53
TENURE
2.8 yrs

Nagesh Mahanthappa

TITLE
President
COMPENSATION
$3M
AGE
54
TENURE
7.5 yrs

Kristina Burow

TITLE
Independent Director
COMPENSATION
$329K
AGE
46
TENURE
5.7 yrs

Ted Myles

TITLE
Independent Director
COMPENSATION
$289K
AGE
47
TENURE
1.4 yrs

Jeffrey Flier

TITLE
Director & Member of Scientific Advisory Board
COMPENSATION
$451K
AGE
71

Amir Nashat

TITLE
Independent Director
COMPENSATION
$326K
AGE
46
TENURE
7.5 yrs

Tim Springer

TITLE
Member of Scientific Advisory Board
COMPENSATION
$404K
AGE
71

Len Zon

TITLE
Member of Scientific Advisory Board

Barry Coller

TITLE
Member of Scientific Advisory Board

Scott Friedman

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Scholar Rock Holding's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Scholar Rock Holding has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

2QK News

Simply Wall St News

2QK Company Info

Description

Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, an inhibitor of the activation of myostatin, which is in Phase II clinical trials for the treatment of spinal muscular atrophy. The company is also developing SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 that is in Phase I clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies. In addition, it is developing a pipeline of novel product candidates for a range of serious diseases, including other neuromuscular disorders, cancer, fibrosis, and anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases; and Adimab, LLC. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Details
Name: Scholar Rock Holding Corporation
2QK
Exchange: DB
Founded: 2012
$415,285,692
29,808,174
Website: http://scholarrock.com
Address: Scholar Rock Holding Corporation
620 Memorial Drive,
2nd Floor,
Cambridge,
Massachusetts, 02139,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS SRRK Common Stock Nasdaq Global Select US USD 24. May 2018
DB 2QK Common Stock Deutsche Boerse AG DE EUR 24. May 2018
Number of employees
Current staff
Staff numbers
93
Scholar Rock Holding employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 03:56
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/03/24
Last earnings filing: 2020/03/12
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.